IL2 and neoplasm: TILs were then peptide-expanded with A2+ healthy donor monocyte-derived dendritic cells (DCs), pulsed overnight with pooled or individual peptides, for 14 days in low IL-2 high IL-15 (as described in “Materials and methods”), and epitope recognition was determined by peptide re-stimulation, staining with custom peptide-MHC (pMHC) tetramers, or tumor cell re-stimulation on day 14.